SEC Form SC 13G/A filed by Ashland Inc. (Amendment)

$ASH
Specialty Chemicals
Consumer Discretionary
Get the next $ASH alert in real time by email
SC 13G/A 1 tv0345-ashlandinc.htm SCHEDULE 13G/A ashlandinc

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934
(Amendment No.: 9)*

Name of issuer:  Ashland Inc

Title of Class of Securities:  Common Stock

CUSIP Number:  044186104

Date of Event Which Requires Filing of this Statement: December 29, 2023

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the following page(s))

 

 

13G

CUSIP No.:  044186104

1.  NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

The Vanguard Group - 23-1945930

2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

A. 

B.  X

3.  SEC USE ONLY

4.  CITIZENSHIP OF PLACE OF ORGANIZATION

Pennsylvania

(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

5.  SOLE VOTING POWER

0

6.  SHARED VOTING POWER

15,622

7.  SOLE DISPOSITIVE POWER

4,900,896

8.  SHARED DISPOSITIVE POWER

68,958

9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,969,854

10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

N/A

11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.70%

12.  TYPE OF REPORTING PERSON

IA

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G
Under the Securities Act of 1934

Item 1(a) - Name of Issuer:

Ashland Inc

Item 1(b) - Address of Issuer's Principal Executive Offices:

8145 Blazer Drive
Wilmington, DE 19808

Item 2(a) - Name of Person Filing:

The Vanguard Group - 23-1945930

Item 2(b) – Address of Principal Business Office or, if none, residence:

100 Vanguard Blvd.
Malvern, PA 19355

Item 2(c) – Citizenship:

Pennsylvania

Item 2(d) - Title of Class of Securities:

Common Stock

Item 2(e) - CUSIP Number

044186104

Item 3 - Type of Filing:

This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

Item 4 - Ownership:

  (a) Amount Beneficially Owned:

  (b) Percent of Class:

 

 

(c)  Number of shares as to which such person has:

(i)  sole power to vote or direct to vote:  

(ii)  shared power to vote or direct to vote:  

(iii)  sole power to dispose of or to direct the disposition of:  

(iv)  shared power to dispose or to direct the disposition of:  

Comments:

The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

Item 5 - Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

No one other person's interest in the securities reported herein is more than 5%.

Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

Not applicable

Item 8 - Identification and Classification of Members of Group:

Not applicable

Item 9 - Notice of Dissolution of Group:

Not applicable

Item 10 - Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  February 13, 2024

By /s/ Ashley Grim
Name: Ashley Grim
Title:  Head of Global Fund Administration

Get the next $ASH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ASH

DatePrice TargetRatingAnalyst
3/26/2025$68.00 → $71.00Neutral → Overweight
Analyst
3/5/2025Buy → Neutral
Seaport Research Partners
8/8/2024$90.00 → $89.00Underweight → Neutral
JP Morgan
4/11/2024$100.00 → $112.00Equal Weight → Overweight
Wells Fargo
3/14/2024$100.00 → $126.00Hold → Buy
Jefferies
3/1/2024$108.00Outperform
Wolfe Research
6/29/2023Outperform → In-line
Evercore ISI
6/26/2023$109.00 → $90.00Outperform → Market Perform
BMO Capital Markets
More analyst ratings

$ASH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Ashland to host 2025 Innovation Day for analysts and investors

    WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is hosting an Innovation Day for analysts and investors at the company's Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person. Participants will join Ashland's executive and senior technology team for an in-depth review of the latest developments and their expanding commercial opportunities. The presentations will detail how these advancements are poised to impact key markets and drive future growth. Following

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland completes sale of Avoca business to Mane

    Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem. "The Avoca business is a strong player in the fragrance fixative space, with a dedicated team and attractive manufacturing capabilities to meet customer needs," said Guillermo Novo

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025

    Sales of $405 million, down 14 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $50 million or 11 percent versus the prior-year quarter. Excluding Portfolio Optimization, sales declined 3 percent versus prior-year quarterLoss from continuing operations of $166 million, or loss of $3.51 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of                $14 million, or $0.28 per diluted shareNet loss of $165 million, or loss of $3.50 per diluted shareA

    $ASH
    Specialty Chemicals
    Consumer Discretionary

$ASH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ASH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ASH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ASH
SEC Filings

See more

$ASH
Leadership Updates

Live Leadership Updates

See more
  • Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

    Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

    Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland Board appoints Ashish K. Kulkarni as new director

    WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corporation. He will serve on the Board's Environmental, Health, Safety and Quality, and Compensation Committees, effective May 6, 2024.  Prior to Celanese, Kulkarni held leadership positions at United Te

    $ASH
    Specialty Chemicals
    Consumer Discretionary

$ASH
Financials

Live finance-specific insights

See more
  • Ashland completes sale of Avoca business to Mane

    Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem. "The Avoca business is a strong player in the fragrance fixative space, with a dedicated team and attractive manufacturing capabilities to meet customer needs," said Guillermo Novo

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland reports financial results for first quarter fiscal 20251, reiterates outlook for full-year fiscal 2025

    Sales of $405 million, down 14 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $50 million or 11 percent versus the prior-year quarter. Excluding Portfolio Optimization, sales declined 3 percent versus prior-year quarterLoss from continuing operations of $166 million, or loss of $3.51 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of                $14 million, or $0.28 per diluted shareNet loss of $165 million, or loss of $3.50 per diluted shareA

    $ASH
    Specialty Chemicals
    Consumer Discretionary
  • Ashland board authorizes quarterly dividend

    WILMINGTON, Del., Jan. 20, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on March 15, 2025, to stockholders of record at the close of business on March 1, 2025. As of December 31, 2024, there were 47,182,862 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings,

    $ASH
    Specialty Chemicals
    Consumer Discretionary

$ASH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more